I am currently the associate director of clinical translation at the Lausanne Branch.  The work of my group focuses on the clinical development of personalized cancer vaccines. Our aim is to enhance whole tumor lysate vaccination approaches and other personalized cancer vaccine approaches by improving the dendritic cell platform and by choosing the most immunogenic antigen with the most practical preparation to be translated rapidly to the clinic. The other focus of the lab is to find the best setting to integrate vaccines in the standard of care treatment plan for ovarian cancer patients and to understand the immune fitness of cancer patients and correlate it with vaccination.